secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001140361-23-042061
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics appoints Dorothy J. Clarke as director effective August 28, 2023
--------------------------------------------------------------------------------

- Ms. Clarke served as VP, Health Care Compliance R&D at Johnson & Johnson until November 2022.
- Board determined Clarke is independent under Nasdaq rules; standard non-employee director comp applies.
- No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K exist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123042061/0001140361-23-042061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123042061/brhc20058268_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-042061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer